参芪糖肾安胶囊含药血清对脂多糖损伤的肾小管上皮细胞活性、超微结构及NLR蛋白3炎性小体的作用机制

张瑞方, 高峰, 杨薇, 李娟, 张轶欧, 姚吉太, 程刚

张瑞方, 高峰, 杨薇, 李娟, 张轶欧, 姚吉太, 程刚. 参芪糖肾安胶囊含药血清对脂多糖损伤的肾小管上皮细胞活性、超微结构及NLR蛋白3炎性小体的作用机制[J]. 实用临床医药杂志, 2023, 27(20): 33-38, 47. DOI: 10.7619/jcmp.20232072
引用本文: 张瑞方, 高峰, 杨薇, 李娟, 张轶欧, 姚吉太, 程刚. 参芪糖肾安胶囊含药血清对脂多糖损伤的肾小管上皮细胞活性、超微结构及NLR蛋白3炎性小体的作用机制[J]. 实用临床医药杂志, 2023, 27(20): 33-38, 47. DOI: 10.7619/jcmp.20232072
ZHANG Ruifang, GAO Feng, YANG Wei, LI Juan, ZHANG Yiou, YAO Jitai, CHENG Gang. Mechanism of Shenqitang Shen'an Capsule containing serum on activity and ultrastructure of renal tubular epithelial cells as well as NLR family pyrin domain containing 3 inflammasome injured by lipopolysaccharide[J]. Journal of Clinical Medicine in Practice, 2023, 27(20): 33-38, 47. DOI: 10.7619/jcmp.20232072
Citation: ZHANG Ruifang, GAO Feng, YANG Wei, LI Juan, ZHANG Yiou, YAO Jitai, CHENG Gang. Mechanism of Shenqitang Shen'an Capsule containing serum on activity and ultrastructure of renal tubular epithelial cells as well as NLR family pyrin domain containing 3 inflammasome injured by lipopolysaccharide[J]. Journal of Clinical Medicine in Practice, 2023, 27(20): 33-38, 47. DOI: 10.7619/jcmp.20232072

参芪糖肾安胶囊含药血清对脂多糖损伤的肾小管上皮细胞活性、超微结构及NLR蛋白3炎性小体的作用机制

基金项目: 

山西省中医药管理局科研课题计划 2022ZYYC004

详细信息
    通讯作者:

    高峰, E-mail: 13935118128@163.com

  • 中图分类号: R692;R334

Mechanism of Shenqitang Shen'an Capsule containing serum on activity and ultrastructure of renal tubular epithelial cells as well as NLR family pyrin domain containing 3 inflammasome injured by lipopolysaccharide

  • 摘要:
    目的 

    探讨参芪糖肾安胶囊含药血清对脂多糖(LPS)损伤的肾小管上皮细胞活性、超微结构及NLR蛋白3(NLRP3)炎性小体的影响。

    方法 

    随机将HK-2细胞分为空白组(HK-2+75 μL 7.5%空白血清)、LPS组(HK-2+LPS+75 μL 7.5%空白血清)、低浓度组(HK-2+LPS+75 μL 2.5%含药血清+75 μL 7.5%空白血清)、中浓度组(HK-2+LPS+75 μL 5%含药血清+75 μL 5%空白血清)、高浓度组(HK-2+LPS+150 μL 10%含药血清)。采用CCK-8法检测细胞存活率; 采用流式细胞仪检测细胞凋亡率; 采用酶联免疫吸附试验(ELISA)检测细胞中白细胞介素-6(IL-6)、白细胞介素-1β(IL-1β)、肿瘤坏死因子-α(TNF-α)水平; 采用电镜检测细胞的超微结构; 采用蛋白质印迹检测细胞中NLRP3和caspase-1蛋白表达。

    结果 

    与空白组相比, LPS组细胞存活率降低,凋亡率及细胞中IL-6、IL-1β、TNF-α水平增高,差异有统计学意义(P < 0.05); 与LPS组相比,低浓度组、中浓度组和高浓度组细胞存活率均增高,凋亡率及细胞中IL-6、IL-1β、TNF-α水平均降低,差异有统计学意义(P < 0.05)。LPS组较空白组出现明显的程序性坏死,细胞体积变大,胞膜大量破裂,细胞大量坏死; 与LPS组相比,低浓度组、中浓度组和高浓度组细胞均有明显改善,坏死的细胞数量减少,仅可见少量细胞线粒体轻度肿胀和空泡样变,且呈剂量依赖性。与空白组相比,LPS组细胞中NLRP3和caspase-1蛋白表达升高,差异有统计学意义(P < 0.05); 与LPS组相比,低浓度组、中浓度组和高浓度组细胞中NLRP3和caspase-1蛋白表达降低,且高浓度组细胞中NLRP3和caspase-1蛋白表达低于低浓度组和中浓度组,差异有统计学意义(P < 0.05)。

    结论 

    参芪糖肾安胶囊含药血清可抑制LPS损伤的肾小管上皮细胞凋亡,增加细胞存活率,改善超微结构,抑制NLRP3炎性小体介导的炎性反应,对急性肾损伤发挥保护作用。

    Abstract:
    Objective 

    To investigate the effects of Shenqitang Shen'an Capsule containing serum on the activity, ultrastructure and NLR family pyrin domain containing 3 (NLRP3) inflammatory vesicles in lipopolysaccharide (LPS)-injured renal tubular epithelial cells.

    Methods 

    HK-2 cells were randomly divided into blank group (HK-2+75 μL 7.5% blank serum), LPS group (HK-2+LPS+75 μL 7.5% blank serum), low concentration group (HK-2+LPS+75 μL 2.5% drug-containing serum+75 μL 7.5% blank serum), medium concentration group (HK-2+LPS+75 μL 5% drug-containing serum+75 μL 5% blank serum), and high concentration group (HK-2+LPS+150 μL 10% drug-containing serum). The cell survival rate was detected by CCK-8; the apoptosis rate was detected by flow cytometry; the levels of interleukin-6 (IL-6), interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α) were detected by enzyme-linked immunosorbent assay (ELISA); the ultrastructure of the cells was detected by electron microscopy; the expression of NLRP3 and caspase-1 protein was detected by protein blotting.

    Results 

    Compared with the blank group, the cell survival rate was reduced, and apoptosis rate, the level of IL-6, IL-1β, and TNF-α in the cells of the LPS group were significantly decreased (P < 0.05). The cell survival rates in the low concentration group, medium concentration group, and high concentration group were higher than those in the LPS group, while the apoptosis rate and the levels of IL-6, IL-1β, and TNF-α in the cells were lower than those in the LPS group (P < 0.05). Compared with the blank group, LPS group showed obvious programmed necrosis, cell volume increased, cell membrane ruptured and cell necrosis. Compared with LPS group, the cells in the low concentration group, medium concentration group and high concentration group were significantly improved, the number of necrotic cells was reduced, and only a few cell mitochondria were slightly swollen and vacuole-like changes were observed in a dose-dependent manner. Compared with the blank group, the protein expression of NLRP3 and caspase-1 in the cells of the LPS group was significantly increased (P < 0.05). The protein expressions of NLRP3 and caspase-1 in the cells of the low concentration group, medium concentration group, and high concentration group were significantly lower than those in the LPS group (P < 0.05), and the protein expressions of NLRP3 and caspase-1 in the cells of the high concentration group were significantly lower than those in the low concentration group and medium concentration group (P < 0.05).

    Conclusion 

    Shenqitang Shen'an Capsule containing serum can inhibit apoptosis of LPS-injured renal tubular epithelial cells, increase cell survival rate, improve ultrastructure, inhibit NLRP3 inflammatory vesicle-mediated inflammatory response, and exert protective effects on AKI.

  • 图  1   各组细胞存活率比较

    A: 不同浓度含药血清细胞存活率比较,与LPS比较, *P < 0.05; B: 各组细胞存活率比较,与空白组比较, *P < 0.05; 与LPS组比较, #P < 0.05; 与低浓度组比较, △P < 0.05; 与中浓度组比较, ▲P < 0.05。

    图  2   各组细胞凋亡率比较

    与空白组比较, *P < 0.05; 与LPS组比较, #P < 0.05; 与低浓度组比较, △P < 0.05; 与中浓度组比较, ▲P < 0.05。

    图  3   各组细胞中IL-6、IL-1β、TNF-α水平比较

    A: 各组IL-6水平比较; B: 各组IL-1β水平比较; C: 各组TNF-α水平比较。与空白组比较, *P < 0.05; 与LPS组比较, #P < 0.05; 与低浓度组比较, △P < 0.05; 与中浓度组比较, ▲P < 0.05。

    图  4   各组细胞超微结构比较(透射电镜,放大20 000倍,标尺5 μm)

    红色箭头为坏死细胞; 橙色箭头为空泡样变。

    图  5   各组细胞中NLRP3、caspase-1蛋白表达比较

    A: 各组蛋白条带; B: 各组NLRP3蛋白表达; C: 各组caspase-1蛋白表达。与空白组比较, *P < 0.05; 与LPS组比较, #P < 0.05; 与低浓度组比较, △P < 0.05; 与中浓度组比较, ▲P < 0.05。

  • [1]

    VAN DER POLL T, SHANKAR-HARI M, WIERSINGA W J. The immunology of sepsis[J]. Immunity, 2021, 54(11): 2450-2464. doi: 10.1016/j.immuni.2021.10.012

    [2]

    LEGRAND M, BELL S, FORNI L, et al. Pathophysiology of COVID-19-associated acute kidney injury[J]. Nat Rev Nephrol, 2021, 17(11): 751-764. doi: 10.1038/s41581-021-00452-0

    [3]

    KELLUM J A, ROMAGNANI P, ASHUNTANTANG G, et al. Acute kidney injury[J]. Nat Rev Dis Primers, 2021, 7(1): 52. doi: 10.1038/s41572-021-00284-z

    [4]

    LIN Q S, LI S, JIANG N, et al. Inhibiting NLRP3 inflammasome attenuates apoptosis in contrast-induced acute kidney injury through the upregulation of HIF1A and BNIP3-mediated mitophagy[J]. Autophagy, 2021, 17(10): 2975-2990. doi: 10.1080/15548627.2020.1848971

    [5]

    WANG S B, CHEN Y, HAN S L, et al. Selenium nanoparticles alleviate ischemia reperfusion injury-induced acute kidney injury by modulating GPx-1/NLRP3/Caspase-1 pathway[J]. Theranostics, 2022, 12(8): 3882-3895. doi: 10.7150/thno.70830

    [6]

    AKHTER J, KHAN J, BAGHEL M, et al. NLRP3 inflammasome in rosmarinic acid-afforded attenuation of acute kidney injury in mice[J]. Sci Rep, 2022, 12(1): 1313. doi: 10.1038/s41598-022-04785-z

    [7] 赵宏波, 张振忠, 刘宁州, 等. 参芪糖肾安冲剂治疗90例早期糖尿病肾病临床疗效观察[J]. 中华中医药杂志, 2014, 29(6): 1909-1912. https://www.cnki.com.cn/Article/CJFDTOTAL-BXYY201406046.htm
    [8]

    YOO J Y, CHA D R, KIM B, et al. LPS-induced acute kidney injury is mediated by Nox4-SH3YL1[J]. Cell Rep, 2020, 33(3): 108245. doi: 10.1016/j.celrep.2020.108245

    [9]

    SCHOLZ H, BOIVIN F J, SCHMIDT-OTT K M, et al. Kidney physiology and susceptibility to acute kidney injury: implications for renoprotection[J]. Nat Rev Nephrol, 2021, 17(5): 335-349. doi: 10.1038/s41581-021-00394-7

    [10]

    WEN Y M, PARIKH C R. Current concepts and advances in biomarkers of acute kidney injury[J]. Crit Rev Clin Lab Sci, 2021, 58(5): 354-368. doi: 10.1080/10408363.2021.1879000

    [11]

    AKILESH S, NAST C C, YAMASHITA M, et al. Multicenter clinicopathologic correlation of kidney biopsies performed in COVID-19 patients presenting with acute kidney injury or proteinuria[J]. Am J Kidney Dis, 2021, 77(1): 82-93, e1. doi: 10.1053/j.ajkd.2020.10.001

    [12] 赵宗江, 张新雪, 冯丽园, 等. 参芪糖肾安颗粒对糖尿病肾病大鼠肾脏保护与氧化应激的影响[J]. 山东中医药大学学报, 2011, 35(6): 529-531. https://www.cnki.com.cn/Article/CJFDTOTAL-SDYX201106025.htm
    [13]

    CAI D L, DUAN H D, FU Y S, et al. Renal tissue damage induced by acute kidney injury in Sepsis rat model is inhibited by cynaropicrin via IL-1β and TNF-α down-regulation[J]. Dokl Biochem Biophys, 2021, 497(1): 151-157. doi: 10.1134/S1607672921020022

    [14]

    DHANISHA S, DRISHYA S, MONY R, et al. Polyphenolic-rich fraction of Pithecellobiumdulce attenuates methotrexate-induced oxidative stress and associated tissue injury by regulating the TNF-α, IL-1β and IL-6 pro-inflammatory cytokines[J]. Int J Funct Nutr, 2021, 2(3): 7. doi: 10.3892/ijfn.2021.17

    [15]

    LI X Y, ZHENG P X, JI T T, et al. LINC00052 ameliorates acute kidney injury by sponging miR-532-3p and activating the Wnt signaling pathway[J]. Aging, 2020, 13(1): 340-350.

    [16]

    CHEN Y H, ZHOU X, WU Y H. The miR-26a-5p/IL-6 axis alleviates sepsis-induced acute kidney injury by inhibiting renal inflammation[J]. Ren Fail, 2022, 44(1): 551-561. doi: 10.1080/0886022X.2022.2056486

    [17] 张泽英, 张辉, 赵昕, 等. shRNA沉默C5aR对LPS诱导的大鼠肾小管上皮细胞损伤的影响[J]. 江苏农业学报, 2017, 33(6): 1327-1332. doi: 10.3969/j.issn.1000-4440.2017.06.019
    [18]

    ZHENG Z H, XU K X, LI C L, et al. NLRP3 associated with chronic kidney disease progression after ischemia/reperfusion-induced acute kidney injury[J]. Cell Death Discov, 2021, 7(1): 324. doi: 10.1038/s41420-021-00719-2

  • 期刊类型引用(1)

    1. 范静,端木玉娟,张异. 中西医结合循证护理在消化内镜下治疗胃肠息肉患者中的应用效果. 河南医学研究. 2023(07): 1322-1326 . 百度学术

    其他类型引用(0)

图(5)
计量
  • 文章访问数:  147
  • HTML全文浏览量:  45
  • PDF下载量:  7
  • 被引次数: 1
出版历程
  • 收稿日期:  2023-06-28
  • 修回日期:  2023-08-30
  • 网络出版日期:  2023-11-05

目录

    /

    返回文章
    返回
    x 关闭 永久关闭

    根据国家关于期刊质量管理的相关要求,为加强学术诚信体系建设,防范学术不端风险,《实用临床医药杂志》要求文章重复率不超过20%。即日起,请作者在向《实用临床医药杂志》投稿前先通过维普、万方等权威数据库进行论文查重检测。作者通过投审稿系统投稿时,需要提交稿件及本文重复率不超过20%的查重检测报告。

    鉴于作者在外部渠道查重易造成论文与成果泄漏,《实用临床医药杂志》官网联系了维普论文检测系统(链接地址:https://vpcs.fanyu.com/personal/jcmp)、万方检测系统(链接地址:http://jcmp.wfcheck.cn/),便于作者进行预查重检测。维普论文检测系统、万方检测系统为第三方检测,具体事宜请作者与检测方接洽(维普联系电话:400-607-5550;万方联系QQ:800856851;电话:18677087062)。

    同时,《实用临床医药杂志》编辑部提醒广大作者尽早关注“实用临床医药杂志”官方微信公众号,并登陆官方网站及投审稿系统进行投稿。

     


    《实用临床医药杂志》官方微信二维码

     

     

    《实用临床医药杂志》官方网站三维码